NEW YORK, June 7 /PRNewswire-FirstCall/ -- Xenomics, Inc. (OTC Bulletin Board: XNOM - News; FWB: XE7), the source of next-generation medical DNA diagnostic technologies, today announced that it has obtained exclusive rights to use a recently discovered genetic marker for Acute Myeloid Leukemia (AML) for the development of new diagnostic tools.
